Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
9,137,601
-
Shares change
-
+2,300,377
-
Total reported value, excl. options
-
$454,036,000
-
Value change
-
+$118,577,913
-
Number of buys
-
31
-
Number of sells
-
-15
-
Price
-
$49.69
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q1 2018
51 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q1 2018.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9,137,601 shares
of 46,239,275 outstanding shares and own 20% of the company stock.
Largest 10 shareholders include MENORA MIVTACHIM HOLDINGS LTD. (2,045,629 shares), Consonance Capital Management LP (1,146,197 shares), ProQuest Associates IV LLC (1,096,024 shares), WELLINGTON MANAGEMENT GROUP LLP (939,875 shares), FMR LLC (864,427 shares), MEITAV DASH INVESTMENTS LTD (447,352 shares), EcoR1 Capital, LLC (402,300 shares), HIGHLINE CAPITAL MANAGEMENT, L.P. (376,823 shares), CREDIT SUISSE AG/ (352,000 shares), and Clal Insurance Enterprises Holdings Ltd (283,500 shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.